All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Guselkumab vs adalimumab for moderate-to-severe plaque psoriasis: A biomarker analysis from the VOYAGE 1 trial
|
In the phase III VOYAGE 1 trial (NCT02207231), guselkumab, a fully human monoclonal antibody that inhibits interleukin (IL)-23, demonstrated superior efficacy vs placebo and adalimumab, a tumor necrosis factor-α (TNF-α) inhibitor, in patients with moderate-to-severe plaque psoriasis.1 Results from a biomarker analysis of a subset of patients in the VOYAGE 1 trial were published in JID Innovations by Blauvelt, et al.1 |
| Key learnings: |
|
While both guselkumab and adalimumab reduced serum levels of key cytokines IL-17A, IL-17F, and IL-22 from baseline at Weeks 4, 24, and 48 (p < 0.001 and p < 0.01, respectively), reductions were greater with guselkumab for IL-17A at Weeks 4 and 48 (p < 0.05), IL-17F at Weeks 4, 24, and 48 (p < 0.05), and IL-22 at Weeks 4 and 48 (p < 0.05), highlighting its superior efficacy in modulating the IL-23/IL-17 pathway in psoriasis. |
|
Treatment with guselkumab led to a more significant impact on the molecular drivers of psoriasis, as demonstrated by a greater normalization of psoriasis-associated gene expression in lesional skin samples at all assessed time points compared with adalimumab. |
|
The molecular pharmacodynamic findings from the study results are consistent with the clinical responses observed in the VOYAGE 1 trial. |
|
The results from this study demonstrate that targeted blockade of the IL-23 pathway with guselkumab may offer improved long-term control of moderate-to-severe plaque psoriasis compared with the broader TNF-α blockade by adalimumab. |
- Blauvelt A, Langley RG, Branigan PJ, et al. Guselkumab reduces disease- and mechanism-related biomarkers more than adalimumab in patients with psoriasis: A VOYAGE 1 substudy. JID Innov. 2024;4(5):100287. DOI: 10.1016/j.xjidi.2024.100287
More about...
Your opinion matters
4 votes - 25 days left ...
Related articles
Newsletter
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox